Table 1. Summary of the Randomized Controlled Trials

First author (Year)	Sample size	Follow up	Intervention	Control		Period	Outcomes	Results	Adverse Events
	Male/Female
	Mean age
Liu22) (2021)	80	none	A:BBCT 100㎖ bid po (n=40)	B:Betahistine mesylate tablets 6㎎ tid po (n=40)		4 weeks	1. Total effective rate (symptoms)2. DHI score	1. A>B (p<0.05)A: 37/40 B: 29/402. A<B (p<0.05)A: 9.71±1.64B: 31.32±2.69	NR
	A: 18/22 B: 20/20
	A: 42.7±8.6B: 40.6±7.4
Qiao23) (2020)	78	3 months	A:BBCT 100㎖ bid po + Epley maneuver (n=41)	B:Epley maneuver (n=37)		2 weeks	1. Total effective rate (symptoms)2. TCM syn. score3. DHI score4. Recurrence rate	1. A>B (p>0.05)A: 39/41 B: 34/372. A<B (p<0.01)A: 5B: 7.53. A<B (p<0.01)A: 24.76±7.03B: 37.98±8.154. A<B (p<0.05)A: 1/39 B: 6/34	NR
	28/50
	41.24 ± 8.19
Zhang24)(2020)	77	none	A:BBCT 200㎖ bid po (n=39)	B:escitalopram oxalate tablet 5㎎ QD (n=38)		2 weeks	1. Total effective rate (DHI)2. DHI score	1. A>B (p<0.05)A: 38/39 B: 28/382. A<B (p<0.05)A: 7.01±3.88B: 15.99±5.11	NR
	A: 22/17 B: 22/16
	A: 53.48±16.42B: 52.45±15.36
Luo25) (2019)	70	3 months	A:BBCT 200㎖ bid po + Epley maneuver (n=35)	B:Epley maneuver (n=35)		2 weeks	1. Total effective rate (symptoms)2. DHI score3. TG, TC level4. LDL, ApoA1 level	1. A>B (p<0.05)A: 32/35 B: 24/352. A<B (p<0.05)A: 3.99±1.40B: 6.92±1.723. A<B (p<0.05)A: 1.53±0.71, 3.20±1.02B: 1.98±1.01, 4.35±1.304. A>B (p<0.05)A: 2.55±0.10, 1.77±0.28B: 2.03±0.47, 1.46±0.19	NR
	A: 15/20 B: 14/21
	A: 46.89±4.04B: 47.23±4.36
Lin26) (2019)	60	none	A:BBCT dose NR bid po (n=30)	B:Betahistine mesylate tablets 6㎎ tid po (n=30)		2 weeks	1. Total effective rate (symptoms)2. DHI score3. VAS score4. TCM syn. score	1. A>B (p<0.05)A: 27/30 B: 23/302. A<B (p<0.05)A: 13.40±3.607B: 24.33±5.9213. A<B (p<0.05)A: 2.97±1.377B: 4.43±1.8704. A<B (p<0.05)A: 6.13±4.696B: 10.50±6.653	none
	A: 11/19 B: 8/22
	A: 50.30±9.083B: 50.13±9.997
Zhang27)(2019)	60	none	A:BBCT 100㎖ bid po (n=30)	B:Betahistine mesylate tablets 6㎎ tid po (n=30)		2 weeks	1. Total effective rate (symptoms)2. DHI score3. VAS score4. TCM syn. score	1. A>B (p<0.05)A: 28/30 B: 22/302. A<B (p<0.05)A: 17B: 263. A<B (p<0.05)A: 2B: 44. A<B (p<0.05)A: 4.80±2.72B: 10.43±2.80	none
	A: 10/20 B: 13/17
	A: 66.70±8.00B: 65.77±8.88
Wu28) (2017)	30	none	A:BBCT dose NR bid po + Epley maneuver (n=15)	B:Epley maneuver (n=15)		3 months	1. Total effective rate (symptoms)2. TG, TC level3. LDL, ApoA1 level	1. A>B (p<0.05)A: 14/15 B: 9/152. A<B (p<0.05)A: 1.57±0.7, 3.33±1.2B: 1.93±1.6, 4.09±1.33. A>B (p<0.05)A: 2.54±0.1, 1.64±0.2B: 2.37±0.3, 1.42±0.1	NR
	A: 9/6 B: 8/7
	A: 58.13±3.1B: 60.02±3.5
Lei29) (2016)	53	3 months	A:BBCT 200㎖ bid po + Epley maneuver (n=23)	B:Epley maneuver (n=30)		2 weeks	1. Total effective rate (symptoms)2. TG, TC, LDL level3. ApoA1 level	1. A>B (p<0.05)A: 22/23 B: 25/302. A<B (p<0.05)A: 1.53±0.89, 3.76±0.54, 2.35±0.17B: 1.96±1.13, 4.01±0.72, 2.41±0.233. A>B (p<0.05)A: 1.54±0.12B: 1.41±0.13	NR
	A: 9/14 B: 11/19
	A: 46.52±11.37B: 49.31±10.52
Liang30) (2016)	86	3 months	A:BBCT dose NR tid po + CRP (n=45)	B:CRP(n=41)		1 month	1. Total effective rate (symptoms)2. Recurrence rate	1. A>B (p<0.05)A: 43/45 B: 34/412. A<B (p<0.05)A: 2.2%B: 14.6%	NR
	A: 19/26 B: 18/23
	A: 53.9±18.7B: 54.6±19.7
Wang31) (2015)	180	6 months	A:BBCT 100㎖ tid po + Epley maneuver (n=60)	B:Epley maneuver (n=60)	C:BBCT 100㎖ tid po (n=60)	1 week	1. Total effective rate (symptoms)	1. A>B or C (p<0.05)A: 58/60 B: 50/60 C: 53/60	NR
	A: 30/30 B: 28/32 C: 25/35
	A: 43.5B: 45.7C: 42.1
Zhu32) (2010)	62	3 months	A:BBCT 100㎖ tid po(n=31)	B:Betahistine 6㎎ tid po(n=31)		1 week	1. Total effective rate (symptoms)2. Recurrence rate	1. A>B (p<0.05)A: 29/31 B: 23/312. A<B (p<0.05)A: 1/29 B: 6/23	NR
	A: 16/15 B: 18/23
	A: 46.2B: 45.6
He33)(2010)	65	none	A:BBCT 100㎖ bid po + Epley maneuver (n=35)	B:Epley maneuver (n=30)		1 week	1. Total effective rate (symptoms)2. Recovery period	1. A>B (p>0.05)A: 32/35 B: 27/302. A<B (p<0.05)A: 7.76±2.79B: 10.55±3.24	NR
	A: 11/24 B: 10/20
	A: 48.15±2.36B: 50.28±3.12

ApoA1: Apolipoprotein A1, BBCT: Banhabaeckchulchunma-tang, CRP: canalith repositioning procedure, DHI: Dizziness Handicap Inventory
LDL: Low density lipoprotein, NR: Not reported, syn.: syndrome, TCM: Traditional Chinese Medicine, TC: Total cholesterol, TG: Triglyceride
VAS: Visual analog scale, qd : quaque die, bid: bis in die, tid: ter in die, po: Per os